Replies to post #16705 on Momenta Pharmaceuticals, Inc. (MNTA)

[Regulardoc]

Would disagree with the Copaxone competition effect and pricing. Glatopa and/or others will be used as leverage by PBMs to move new starts away from the orals.

If you can purchase Glatopa for $25000 annually, they will move other MS drugs to Third tier or noncoverage status with prior auth required.